Spanish
Mitral & Tricuspid Replacement by Trans-jugular & Trans-Femoral approach.
Hits: 208 | Stock No: #21002
USD5000000
Project Details
Minimum investment per investor:
1000000
Country:
Israel
State:
Haifa
Reason for needing Capital:
Research & Development
Stage:
Finished product
Ideal Investor Role:
Equity partner
Highlights:
The company have a patent pending.
The R&D process was completed.
We have started the animal clinical trials.
We will be ready to start the Exit process in 4 years.
The plan is to open a US entity to be close to the future Exit proposals by Abbott, Medtronic and Edwards Lifesciences.
The R&D process was completed.
We have started the animal clinical trials.
We will be ready to start the Exit process in 4 years.
The plan is to open a US entity to be close to the future Exit proposals by Abbott, Medtronic and Edwards Lifesciences.
What you offer to investors?:
The company value today $25 Million, we offer for the $5 Million investment, 20% of the company shares.
We are a start-up company developing an out of the box solution for Mitral and Tricuspid Heart Valve replacement by trans-jugular and trans-femoral approach instead of an operation.
The company have a patent pending, the R&D was completed, and the animal clinical trials have begun to get the FDA and CE approvals.
The procedure is reimbursed, in the US alone being done 40,000 Mitral procedures and 20,000 Tricuspid procedures and the same numbers in the rest of the world.
Contact info
Please sign in so you can view the contact information!
Similar Projects
